EQ Profile
Equillium, Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing innovative treatments for severe autoimmune and immuno-inflammatory disorders with significant unmet medical needs. The company's primary focus is on its lead product candidate, itolizumab (EQ001), a monoclonal antibody that targets the novel immune checkpoint receptor CD6. Itolizumab is currently undergoing Phase III clinical trials for the treatment of acute graft-versus-host disease, a serious condition that can occur after a stem cell or bone marrow transplant. The drug has also completed a Phase Ib clinical trial for asthma and is advancing through a Phase Ib clinical trial for lupus nephritis.
In addition to itolizumab, Equillium is developing other therapeutic candidates to address various medical conditions. EQ101 is being investigated for the treatment of cutaneous T cell lymphoma and alopecia areata, while EQ102 aims to address multiple gastrointestinal diseases. These candidates reflect the company's commitment to expanding its pipeline and addressing a broad range of serious health conditions.
Equillium's innovative approach centers on targeting specific immune pathways to modulate the immune system's response, potentially offering new treatment options for patients with challenging and poorly addressed conditions. The company's research and development efforts are focused on leveraging cutting-edge science to deliver transformative therapies that can improve patient outcomes.
Founded as Attenuate Biopharmaceuticals, Inc. and rebranded to Equillium, Inc. in May 2017, the company was incorporated in 2017 and is headquartered in La Jolla, California. With its advanced clinical-stage pipeline and strategic focus on high-need therapeutic areas, Equillium is positioned at the forefront of biopharmaceutical innovation in the field of autoimmune and inflammatory diseases.
|
